Oncology in Clinical Practice最新文献

筛选
英文 中文
Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography over conventional imaging studies to detect malignant lesions in staging and restaging after radically treated primary and recurrent locoregional cutaneous melanoma 18f -氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描对原发性和复发性局部皮肤黑色素瘤根治后恶性病变分期和再分期的诊断价值
IF 0.5
Oncology in Clinical Practice Pub Date : 2022-12-15 DOI: 10.5603/ocp.2022.0051
Z. Dancheva, A. Klisarova, S. Strashilov, V. Nanev, A. Konsoulova
{"title":"Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography over conventional imaging studies to detect malignant lesions in staging and restaging after radically treated primary and recurrent locoregional cutaneous melanoma","authors":"Z. Dancheva, A. Klisarova, S. Strashilov, V. Nanev, A. Konsoulova","doi":"10.5603/ocp.2022.0051","DOIUrl":"https://doi.org/10.5603/ocp.2022.0051","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82475866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recommendations for prevention of SARS-CoV-2 infection in immunocompromised patients 免疫功能低下患者预防SARS-CoV-2感染的建议
IF 0.5
Oncology in Clinical Practice Pub Date : 2022-12-09 DOI: 10.5603/ocp.2022.0035
K. Tomasiewicz, A. Dębska-Ślizień, M. Durlik, K. Giannopoulos, I. Hus, P. Rutkowski
{"title":"Recommendations for prevention of SARS-CoV-2 infection in immunocompromised patients","authors":"K. Tomasiewicz, A. Dębska-Ślizień, M. Durlik, K. Giannopoulos, I. Hus, P. Rutkowski","doi":"10.5603/ocp.2022.0035","DOIUrl":"https://doi.org/10.5603/ocp.2022.0035","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72407723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atezolizumab in the treatment of patients with breast cancer Atezolizumab用于治疗乳腺癌患者
IF 0.5
Oncology in Clinical Practice Pub Date : 2022-12-07 DOI: 10.5603/ocp.2022.0036
K. Pogoda, A. Jagiełło-Gruszfeld, M. Kunkiel, W. Olszewski
{"title":"Atezolizumab in the treatment of patients with breast cancer","authors":"K. Pogoda, A. Jagiełło-Gruszfeld, M. Kunkiel, W. Olszewski","doi":"10.5603/ocp.2022.0036","DOIUrl":"https://doi.org/10.5603/ocp.2022.0036","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91206322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epithelioid inflammatory myofibroblastic sarcoma of the lung ALK+/ NTRK+/ PD-L1+ 肺上皮样炎性肌纤维母细胞肉瘤ALK+/ NTRK+/ PD-L1+
IF 0.5
Oncology in Clinical Practice Pub Date : 2022-12-06 DOI: 10.5603/ocp.2022.0049
G. Gaggero, Davide Taietti, Veronica Parrella, Camilla Gennaioli, A. Guadagno
{"title":"Epithelioid inflammatory myofibroblastic sarcoma of the lung ALK+/ NTRK+/ PD-L1+","authors":"G. Gaggero, Davide Taietti, Veronica Parrella, Camilla Gennaioli, A. Guadagno","doi":"10.5603/ocp.2022.0049","DOIUrl":"https://doi.org/10.5603/ocp.2022.0049","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82181440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Niraparib maintenance in newly diagnosed advanced ovarian cancer — review and case series 尼拉帕尼维持在新诊断的晚期卵巢癌-回顾和病例系列
IF 0.5
Oncology in Clinical Practice Pub Date : 2022-11-24 DOI: 10.5603/ocp.2022.0048
Martyna Tyszka, R. Stec
{"title":"Niraparib maintenance in newly diagnosed advanced ovarian cancer — review and case series","authors":"Martyna Tyszka, R. Stec","doi":"10.5603/ocp.2022.0048","DOIUrl":"https://doi.org/10.5603/ocp.2022.0048","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78067076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nivolumab in the treatment of thoracic cancer — new possibilities 纳武单抗治疗胸腔癌-新的可能性
IF 0.5
Oncology in Clinical Practice Pub Date : 2022-11-16 DOI: 10.5603/ocp.2022.0033
M. Knetki-Wróblewska, K. Wojas-Krawczyk
{"title":"Nivolumab in the treatment of thoracic cancer — new possibilities","authors":"M. Knetki-Wróblewska, K. Wojas-Krawczyk","doi":"10.5603/ocp.2022.0033","DOIUrl":"https://doi.org/10.5603/ocp.2022.0033","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81487511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overall survival of patients with metastatic KRAS wild type colorectal cancer patients treated with anti-EGFR third line monotherapy 抗egfr三线单药治疗转移性KRAS野生型结直肠癌患者的总生存期
IF 0.5
Oncology in Clinical Practice Pub Date : 2022-11-16 DOI: 10.5603/ocp.2022.0044
S. Dębska-Szmich, M. Krakowska, Katarzyna Staniecka, Paulina Krzeptowska, Jakub Dębski, Maria Dzierżak, M. Wąsik, Joanna Gadzinowska, Maja Habib-Lisik
{"title":"Overall survival of patients with metastatic KRAS wild type colorectal cancer patients treated with anti-EGFR third line monotherapy","authors":"S. Dębska-Szmich, M. Krakowska, Katarzyna Staniecka, Paulina Krzeptowska, Jakub Dębski, Maria Dzierżak, M. Wąsik, Joanna Gadzinowska, Maja Habib-Lisik","doi":"10.5603/ocp.2022.0044","DOIUrl":"https://doi.org/10.5603/ocp.2022.0044","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74674159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expert recommendations on diagnostic-therapeutic management of melanoma patients 黑色素瘤患者诊断和治疗管理的专家建议
IF 0.5
Oncology in Clinical Practice Pub Date : 2022-11-09 DOI: 10.5603/ocp.2021.0042
P. Rutkowski, P. Wysocki, K. Kozak, A. Nasierowska-Guttmejer, A. Jeziorski, W. Wysocki, E. Kalinka, T. Świtaj, G. Kamińska-Winciorek, A. Czarnecka, H. Koseła-Paterczyk, B. Cybulska-Stopa, Piotr Wiśniewski, A. Szumera-Ciećkiewicz, M. Zdzienicki, M. Ziobro, J. Fijuth, A. Kawecki, A. Tysarowski, B. Romanowska-Dixon, A. Markiewicz, M. Dedecjus, T. Kubiatowski, Kamil Dolecki, Hanna Tchórzewska-Korba, L. Rudnicka, W. Owczarek, M. Krzakowski
{"title":"Expert recommendations on diagnostic-therapeutic management of melanoma patients","authors":"P. Rutkowski, P. Wysocki, K. Kozak, A. Nasierowska-Guttmejer, A. Jeziorski, W. Wysocki, E. Kalinka, T. Świtaj, G. Kamińska-Winciorek, A. Czarnecka, H. Koseła-Paterczyk, B. Cybulska-Stopa, Piotr Wiśniewski, A. Szumera-Ciećkiewicz, M. Zdzienicki, M. Ziobro, J. Fijuth, A. Kawecki, A. Tysarowski, B. Romanowska-Dixon, A. Markiewicz, M. Dedecjus, T. Kubiatowski, Kamil Dolecki, Hanna Tchórzewska-Korba, L. Rudnicka, W. Owczarek, M. Krzakowski","doi":"10.5603/ocp.2021.0042","DOIUrl":"https://doi.org/10.5603/ocp.2021.0042","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90565296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Evaluation of survival outcomes in patients with sporadic, advanced, unresectable well-differentiated pancreatic neuroendocrine tumors treated initially with octreotide LAR and subsequent therapeutical approaches on relapse. A real-world data set 评估散发性、晚期、不可切除的高分化胰腺神经内分泌肿瘤患者的生存结果,这些患者最初接受奥曲肽LAR治疗,随后接受复发治疗。真实世界的数据集
IF 0.5
Oncology in Clinical Practice Pub Date : 2022-10-28 DOI: 10.5603/ocp.2022.0045
A. Kolasińska-Ćwikła, Klaudia Gutowska, K. Osowiecka, T. Bednarczuk, Anna Słoniewska, K. Roszkowska-Purska, J. Pałucki, J. Cwikła
{"title":"Evaluation of survival outcomes in patients with sporadic, advanced, unresectable well-differentiated pancreatic neuroendocrine tumors treated initially with octreotide LAR and subsequent therapeutical approaches on relapse. A real-world data set","authors":"A. Kolasińska-Ćwikła, Klaudia Gutowska, K. Osowiecka, T. Bednarczuk, Anna Słoniewska, K. Roszkowska-Purska, J. Pałucki, J. Cwikła","doi":"10.5603/ocp.2022.0045","DOIUrl":"https://doi.org/10.5603/ocp.2022.0045","url":null,"abstract":"Introduction. Somatostatin analogs (SSA) are widely used in the treatment of patients with well-differentiated neuroendocrine tumors (NET). There are limited reports about the role of octreotide LAR in first-line therapy of advanced pancreatic NET (pan-NET). This study aimed to evaluate the antiproliferative effect of octreotide LAR in patients with sporadic, advanced, unresectable pan-NET, based on progression-free survival (PFS). Material and methods. This was a retrospective analysis of 374 patients with pan-NET; 41 treated subjects were included. The primary endpoint was PFS defined as the time to disease progression (Response Evaluation Criteria in Solid Tumors: RECIST). Univariate and multivariate analyses were used to identify predictors of PFS. Secondary endpoints included overall survival (OS) and second-line therapies after progression. Results. There were 13 (32%) patients with G1 pan-NET and 28 (68%) with pan-NET G2, 21 female and 20 male, with mean age 55.4 (range 29–87). Median PFS was 9.0 months (95% CI 4.7–24.0). Subgroup analysis revealed that G1 and no-bulky liver disease (< 25% liver volume) were associated with significantly longer PFS. Univariate analysis confirmed a correlation between G1 [0.34 hazard rate (HR) of progression or death (95% CI 0.16–0.72)] and no-bulky liver disease HR = 0.31 (95% CI 0.13–0.71). Multivariable analysis demonstrated that only functional (secretory) pan-NET was associated as an independent factor with shorter PFS HR = 2.97 (95% CI 1.0–8.74). Median OS was 105.4 months (95% CI 40.0–172.0). After relapse following initial systemic therapy, the second line was used in 34 subjects, 3rd line in 18th, and 4th line in 9 subjects. Conclusions. Octreotide LAR shows moderate antiproliferative activity in pan-NET. Prolonged PFS may be associated with G1 and low-volume metastatic liver disease. In patients with progressive disease, various treatment options were used, which resulted in median OS of 105.4 months.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76730247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case report of radiation-induced lung injury with trastuzumab emtansine: the lung also matters 曲妥珠单抗emtansine治疗放射性肺损伤病例报告:肺也很重要
IF 0.5
Oncology in Clinical Practice Pub Date : 2022-10-28 DOI: 10.5603/ocp.2022.0043
E. Gurlek, Mustafa YILMAZ, M. Gultekin, S. Aksoy, F. Yıldız
{"title":"Case report of radiation-induced lung injury with trastuzumab emtansine: the lung also matters","authors":"E. Gurlek, Mustafa YILMAZ, M. Gultekin, S. Aksoy, F. Yıldız","doi":"10.5603/ocp.2022.0043","DOIUrl":"https://doi.org/10.5603/ocp.2022.0043","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84709226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信